BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

...own barrage of tests. Steve Schow, an industry consultant and former VP of R&D at Telik Inc....
BioCentury | Apr 13, 2017
Targets & Mechanisms

Allosteric en-ABL-ement

...Bristol-Myers Squibb Co. According to Steve Schow, industry consultant and former VP of R&D at Telik Inc....
BioCentury | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

...in addition to blocking SERT. Steve Schow, industry consultant and former VP of R&D at Telik Inc....
...inhibitor, we are more or less done exploiting this transporter in drug design." In 2014, Telik...
BioCentury | Sep 24, 2015
Tools & Techniques

Poppy-free opiates

..."highly specialized and costly processes." Steve Schow, industry consultant and former VP of R&D at Telik Inc....
BioCentury | Jan 22, 2015
Targets & Mechanisms

Unearthing antibiotics

...ready for the clinic." According to Steve Schow, consultant and former VP of R&D at Telik Inc....
...really been a major issue for cationic antimicrobials," he said. MabVax Therapeutics Inc. reverse-merged with Telik...
BioCentury | Dec 11, 2014
Cover Story

Universal reversal for heparin

...anticoagulant effect. The path forward Steve Schow, industry consultant and former VP of R&D at Telik Inc....
...become the first drug based on a dendritic scaffold. MabVax Therapeutics Inc. reverse merged with Telik...
BioCentury | Sep 1, 2014
Company News

MabVax, Telik deal

...MabVax reverse-merged with Telik in a stock deal. Following the close, MabVax shareholders own 82% of...
...through the sale of 1.2 million MabVax shares at $2.59, which were converted to 2.23 Telik...
...stock for $1.5 million (see BioCentury, May 19). MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
BioCentury | Aug 4, 2014
Emerging Company Profile

Myelo: Preventing neutropenia

...are in Phase II testing: Telintra ezatiostat hydrochloride, an IV peptidomimetic glutathione S-transferase inhibitor from Telik Inc....
...Companies and Institutions Mentioned Myelo Therapeutics GmbH , Berlin, Germany PledPharma AB , Stockholm, Sweden Telik Inc....
BioCentury | May 19, 2014
Company News

MabVax, Telik deal

...in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik...
...president, CEO and chairman of the combined company; and Michael Wick, president and CEO of Telik...
...Telik, which could not be reached for details. MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
BioCentury | Mar 27, 2014
Strategy

Teaching translation

...projects. Steven Schow, an adviser on the program and VP of R&D at cancer company Telik Inc....
...Alto, Calif. Stanford University , Stanford, Calif. Stanford University School of Medicine , Stanford, Calif. Telik Inc....
Items per page:
1 - 10 of 297
BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

...own barrage of tests. Steve Schow, an industry consultant and former VP of R&D at Telik Inc....
BioCentury | Apr 13, 2017
Targets & Mechanisms

Allosteric en-ABL-ement

...Bristol-Myers Squibb Co. According to Steve Schow, industry consultant and former VP of R&D at Telik Inc....
BioCentury | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

...in addition to blocking SERT. Steve Schow, industry consultant and former VP of R&D at Telik Inc....
...inhibitor, we are more or less done exploiting this transporter in drug design." In 2014, Telik...
BioCentury | Sep 24, 2015
Tools & Techniques

Poppy-free opiates

..."highly specialized and costly processes." Steve Schow, industry consultant and former VP of R&D at Telik Inc....
BioCentury | Jan 22, 2015
Targets & Mechanisms

Unearthing antibiotics

...ready for the clinic." According to Steve Schow, consultant and former VP of R&D at Telik Inc....
...really been a major issue for cationic antimicrobials," he said. MabVax Therapeutics Inc. reverse-merged with Telik...
BioCentury | Dec 11, 2014
Cover Story

Universal reversal for heparin

...anticoagulant effect. The path forward Steve Schow, industry consultant and former VP of R&D at Telik Inc....
...become the first drug based on a dendritic scaffold. MabVax Therapeutics Inc. reverse merged with Telik...
BioCentury | Sep 1, 2014
Company News

MabVax, Telik deal

...MabVax reverse-merged with Telik in a stock deal. Following the close, MabVax shareholders own 82% of...
...through the sale of 1.2 million MabVax shares at $2.59, which were converted to 2.23 Telik...
...stock for $1.5 million (see BioCentury, May 19). MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
BioCentury | Aug 4, 2014
Emerging Company Profile

Myelo: Preventing neutropenia

...are in Phase II testing: Telintra ezatiostat hydrochloride, an IV peptidomimetic glutathione S-transferase inhibitor from Telik Inc....
...Companies and Institutions Mentioned Myelo Therapeutics GmbH , Berlin, Germany PledPharma AB , Stockholm, Sweden Telik Inc....
BioCentury | May 19, 2014
Company News

MabVax, Telik deal

...in a stock deal to create a publicly traded company named MabVax Therapeutics Holdings Inc. Telik...
...president, CEO and chairman of the combined company; and Michael Wick, president and CEO of Telik...
...Telik, which could not be reached for details. MabVax Therapeutics Inc. , San Diego, Calif. Telik Inc....
BioCentury | Mar 27, 2014
Strategy

Teaching translation

...projects. Steven Schow, an adviser on the program and VP of R&D at cancer company Telik Inc....
...Alto, Calif. Stanford University , Stanford, Calif. Stanford University School of Medicine , Stanford, Calif. Telik Inc....
Items per page:
1 - 10 of 297